Carlet C, Dalle S, Leccia MT, et al. - In the present study, the researchers sought to assess late-onset adverse events (AEs) in melanoma patients treated with anti-PD1 administered at least 2 years in a real-life setting. Between January 2013 and November 2019, 119 patients who received anti-PD1 during at least 2 years were involved. Study participants received nivolumab (n = 53) or pembrolizumab (n = 66). The findings suggest that late-onset AEs could occur after 2 years of anti-PD1 therapy. Late-onset AEs are common and usually mild or moderate. Early-onset AEs and prolonged anti-PD1 treatment may raise the chance of late-onset AEs.